Dynamic42 GmbH has successfully completed a six-figure fundraising in early summer 2019 as an important step towards future growth. The new investment round will enable Dynamic42 to further its product development and market expansion.
bm|t beteiligungsmanagement thüringen gmbh (bm|t) made the investment through its Thüringer Start-up Fund (TSF). Dr. Knut Rennert and Martin Raasch, managing directors at Dynamic42, agree “the investment will significantly scale up our operations and open new business opportunities. We are pleased to have bm|t on board as a strong partner at our side. We highly appreciate the support and trust bm‑t has given us.”
Dynamic42, based in Jena, was founded in 2018 and develops microfluidic chip systems to cultivate human cells mimicking realistic body conditions. “Our systems uniquely incorporate adjustments for body temperature and nutrient supply, which has been used in cytological research over a long time. Our systems also offer the possibility to expose human cells to pressure and shearing through simulated blood flow. Additionally, our system is able to integrate a three-dimensional cell structure with immune cells into the chip. Both components imitate the multi-cell structure of the human body significantly better than existing models and provide a realistic simulation of cell functions and interactions”, explains Martin Raasch. The team has successfully established organ models of the human liver, intestines and lung.
“We started with the idea to rebuild and cultivate simple blood vessels under realistic body conditions. Those components remain an integral part of our models as they enable the interconnection of organs and function as important transmitters in case of diseases (esp. relevant for immune cells). As we moved to the replication of entire organ models, such as the liver, our project gained complexity. The liver is one of the most critical organs for drug interactions. General effects, side effects and potential toxicity of new drugs and therapies are better investigated on realistic human cell models than on two-dimensional cell cultures and animal models only. Our goal is to improve drug safety and data quality in preclinical studies, as well as to reduce side effects and the need for animal experiments”, said Dr. Knut Rennert. “The anatomically correct placement of human cells and the integration of functional immune cells especially in connection with a web-based classification of vitality and functionality parameters offer high value to clients and large potential to gain additional market share in the rapidly growing organ-on-chip market”, stated Stefan Jahn, investment manager at bm|t.
bm|t beteiligungsmanagement thüringen GmbH is a fully-owned subsidiary of Thüringer Aufbaubank based in Erfurt, Germany. It is the leading address for venture capital and private equity investments in Thuringia. bm|t currently manages 8 funds with a total volume of EUR 320mm. It invests in innovative firms in nearly all sectors and corporate development stages – from seed to growth phase and business successions. (www.bm‑t.com)
About Dynamic42 GmbH:
Dynamic42 GmbH was founded in 2018 as a spin-off of the Center for Sepsis Control and Care (CSCC) from the university clinic in Jena. Dynamic42 develops and distributes humane micro physiological systems (MPS) and organ-on-chip models with integrated immune system components for research and testing of pharmaceutical products as well as new therapies with nanoparticles, chemicals and food additives. (www.dynamic42.com)